Behavioral and neurochemical interactions between cocaine and buprenorphine: implications for the pharmacotherapy of cocaine abuse

EE Brown, JM Finlay, JT Wong, G Damsma and HC Fibiger

Division of Neurological Sciences, Department of Psychiatry, Vancouver, British Columbia, Canada.

Intravenous self-administration studies in nonhuman primates suggest that the opioid receptor agonist-antagonist buprenorphine may be useful in the pharmacotherapy of cocaine abuse. In the present studies, behavioral and neurochemical interactions between cocaine and buprenorphine were examined using a conditioned place preference (CPP) procedure and in vivo microdialysis. Cocaine-induced CPP was linearly related to the dose administered (0-5.0 mg/kg). Buprenorphine (0-0.9 mg/kg) also elicited CPP in a dose-related manner; an inverted U-shaped function was obtained. Subthreshold doses of cocaine (1.5 mg/kg) and buprenorphine (0.01 mg/kg), themselves incapable of eliciting CPP, produced a significant CPP when given together. Moderate doses of cocaine (5.0 mg/kg) and buprenorphine (0.075 mg/kg), which were individually capable of eliciting CPP, produced a significantly larger CPP when given in combination. In the in vivo microdialysis studies, a low dose of buprenorphine (0.01 mg/kg) produced a progressive increase in extracellular dopamine in the nucleus accumbens, reaching approximately 200% of basal levels after 5 hr. Cocaine (5.0 mg/kg) rapidly increased extracellular dopamine concentrations (180% of basal values within 20 min), which returned to baseline in 2 to 3 hr. This effect of cocaine was significantly potentiated by coadministering buprenorphine (0.01 mg/kg); under this condition the peak increase in extracellular dopamine reached 260% of baseline values. These neurochemical findings are consistent with the CPP results and indicate that buprenorphine can interact with cocaine in a synergistic manner. In contrast to previous speculations, these results suggest that buprenorphine may enhance rather than attenuate the rewarding properties of cocaine.

Volume 256, Issue 1, pp. 119-126, 01/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. M. Platt, D. M. Grech, J. K. Rowlett, and R. D. Spealman Discriminative Stimulus Effects of Morphine in Squirrel Monkeys: Stimulants, Opioids, and Stimulant-Opioid Combinations J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1092 - 1100. [Abstract] [Full Text]

				J. M. van Ree, M. A. F. M. Gerrits, and L. J. M. J. Vanderschuren Opioids, Reward and Addiction: An Encounter of Biology, Psychology, and Medicine Pharmacol. Rev., June 1, 1999; 51(2): 341 - 396. [Abstract] [Full Text] [PDF]

				S. E. Hemby, C. Co, S. I. Dworkin, and J. E. Smith Synergistic Elevations in Nucleus Accumbens Extracellular Dopamine Concentrations during Self-Administration of Cocaine/Heroin Combinations (Speedball) in Rats J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 274 - 280. [Abstract] [Full Text]

				J. K. Rowlett, K. M. Wilcox, and W. L. Woolverton Self-Administration of Cocaine-Heroin Combinations by Rhesus Monkeys: Antagonism by Naltrexone J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 61 - 69. [Abstract] [Full Text]

				H. L. Kimmel and S. G. Holtzman Mu Opioid Agonists Potentiate Amphetamine- and Cocaine-Induced Rotational Behavior in the Rat J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 734 - 746. [Abstract] [Full Text]

				R. S. Schottenfeld, J. R. Pakes, A. Oliveto, D. Ziedonis, and T. R. Kosten Buprenorphine vs Methadone Maintenance Treatment for Concurrent Opioid Dependence and Cocaine Abuse Arch Gen Psychiatry, August 1, 1997; 54(8): 713 - 720. [Abstract] [PDF]